+ 1.20
+ 0.35%
+ 0.39
+ 0.12%
+ 1.17
+ 0.28%

Jefferies Raises OraSure Technologies Price Target

December 31, 2014 9:08 am
Share to Linkedin Share to Twitter Share to Facebook Share to Print License More

Jefferies raised its price target on OraSure Technologies, Inc. (NASDAQ: OSUR) from $10 to $12 and maintained a Buy rating.

Analyst Brandon Couillard noted that “Nielsen's monthly data for OSUR's OTC HIV test indicates retail unit volume sell-through increased 6 percent sequentially in the latest period (four-weeks ending Dec. 20), reflecting an encouraging reversal from last month (-9 percent in Nov.), despite absorbing a likely headwind from the timing of Thanksgiving & lack of media support.”

Couillard expected “domestic OTC HIV test volumes to remain tepid near term, the latest experience adds confidence to our 2015 revenue forecast for the product (-6 percent). Separately, we note that our model does not factor any contribution from a potential OUS
launch of the OTC HIV test, which could gain CE mark approval in early-2015.”

The analyst note concluded that “heading into 2015, OSUR remains one of our favorite small-cap growth ideas & we view multiple expansion as justified, given the prospects of an accelerating product revenue growth trajectory (+9 percent vs. flat in 2014E) and multiple discrete EBIT tailwinds (~$15M / +$0.25 impact), which should drive a meaningful profitability/cash flow infection next year.”

The $12 price target represented a 10-year horizon in the firm’s DCF model & implied an EV of 4.1x 2016E revenue.

OraSure Technologies closed Tuesday at $10.17, down 0.97 percent.

For the latest in financial news, exclusive stories, memes follow Benzinga on Twitter, Facebook & Instagram. For the best interviews, stock market talk & videos, subscribe to our YouTube channel.

Related Articles

Jefferies: 10 Buyout Targets To Own During The M&A Boom

UPDATE: Jefferies Assumes Coverage on OraSure Technologies at Buy on Weaker Demand Trend Concerns

UPDATE: Jefferies Initiates Buy, $14 PT on OraSure Tech on New Product Cycle

Jefferies Out Negative On OraSure, Says It's Unclear How Much Of $143M Consumer Genomics Contract Is Truly Incremental To Its Current Run-Rate